BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Glaucoma Drug Developer Altheos, Inc. Adds $12.5 Million to Series A Round


2/10/2012 8:29:28 AM

San Francisco Business Times by Ron Leuty, Reporter

Altheos Inc. raised an additional $12.5 million — pushing its Series A round to a total of $32.5 million — as the South San Francisco company enters a mid-stage study of a glaucoma drug.

Funding has come from Bay City Capital, Novo A/S, Canaan Partners and additional investors, the company said Thursday.

The expanded Series A round will allow Altheos to complete the Phase II clinical program for ATS-907, which is designed as an eye drop to reduce elevated intraocular pressure in primary open angle glaucoma and ocular hypertension. The first patent has been dosed in a Phase IIa trial of the drug, the company said.

ATS-907 is one of a number of so-called ROCK compounds licensed from Asahi Kasei Pharma. Inhibitors of Rho kinase, or ROCK, are believed to reduce cellular “stiffness,” reduce intraocular pressure and could reduce inflammation in the eye, Altheos said.

Altheos CEO Dr. Henry Hsu and Ken Kengatharan started the company in 2009.

The initial $20 million was raised in 2010.



   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->